The AstraZeneca PLC ADR AZN rose 1.64% to $73.00 Wednesday, on what proved to be an all-around mixed trading session for the ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

AstraZeneca PLC closed 19.58% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca has presented results for the SERENA-6 trial at the American Society for Medical Oncology (ASMO)'s 2025 ...

The latest trading session saw Astrazeneca (AZN) ending at $71.93, denoting a -1.24% adjustment from its last day's close.

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing ...

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He ...